Denmark's Evaxion Q1 net loss widens

Evaxion A/S

07/05/2026 12:43

Overview

Denmark vaccine developer reported Q1 net loss widened yr/yr

Q1 net loss increased due to lower financial income from derivative remeasurement

Company maintains cash runway to fund operations into second half of 2027

Outlook

Company maintains cash runway to fund operations into second half of 2027

Result Drivers

LOWER FINANCIAL INCOME - Q1 net loss widened due to lower financial income from derivative liability remeasurement compared to prior year

R&D SPENDING - Slight increase in R&D expenses as pipeline progressed according to plan

LOWER ADMIN COSTS - General and administrative expenses decreased, mainly due to lower capital market costs

Company press release: ID:nGNX5q1K15

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.01
Q1 Net Income
-$3.63 mln
Q1 Pretax Profit
-$3.85 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Evaxion A/S is $10.00, about 126.8% above its May 6 closing price of $4.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)